Review
Aug 2026
KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms
KRAS-mutant NSCLC is transitioning from historically untargetable disease to a therapeutically actionable subset, and future progress hinges on resistance-directed combinations, biomarker-guided personalization, expansion to non-G12C mutants, and evaluation in earlier disease settings.
A. Kapoor, Bipinesh Sansar, Anuj Gupta et al.
· Medical Oncology · 0 citations